Indian Pharma Market - October 2015 Highlights
Indian Pharma Market (IPM) clocked 8601 Crs and grew at 21.8% in Oct 2015
Companies:
DPCO, Non DPCO & Non-Scheduled Para 19 Market:
Therapy:
Companies:
- In the top 10, Pfizer grew at 25.4%; GSK at 23.9% & Abbott at 23.6%
- 22 companies crossed the growth of IPM in the top 50
- Bharat Serums had the highest growth of 62.7% followed by AstraZeneca at 57.0% & Wockhardt at 50.4 %v in the top 50
- Glenmark has the highest growth of 43.6% followed by Micro at 33.6% & Alembic at 31.4% in the 11-20 ranked
- Wockhardt has the highest growth at 50.4% followed by MSD 40.1% & Unichem at 26.6% in the 21-30 ranked
- JBCPL at 43.7% has the highest growth in the 31-40 ranked
- Troikaa has the highest growth at 37.0% followed by Hetero at 30.6% & Win-Medicare at 18.9% in the 41-50 ranked
- Boehringer grew at 69.6% followed by Centaur at 37.2% & Corona at 33.4% in the 51-60 ranked
- Fresenius Kabi grew at 66.8% followed by RPG by 37.9% followed by Geno at 23.6% in the 61-70 ranked Corporate
- MSD enters the 1000 Cr Club, Bharat Serums enters the 500 Cr Club, Hegde & Hegde in 300 Cr Club, Geno Pharma in 200 Cr Club, Veritaz in 100 Cr Club on MAT basis
- Ind-Swift & Shreya, which had declined for years are staging a strong revival on growth as well as 6 month trends look positive.
- 100 plus ranked companies like Alarsin and Vanguard are showing a strong positive upswing on monthly basis.
- Indian cos grew at 21.4% versus 23.5% for MNCs in October 2015
- In the top 50 in MNCs, AstraZeneca grew at 57.0%, MSD grew by 40.1% followed by & Pfizer at 25.4%
DPCO, Non DPCO & Non-Scheduled Para 19 Market:
- DPCO molecules market grew at 15.4% whereas the non DPCO market grew by 22.9% & Non-Sch Para 19 Market at 20.9% resulting in an overall growth of 21.8% for October 2015
Therapy:
- 8 therapies have outgrown the IPM growth
- Respiratory Market grew at 21.8%
- Gastrointestinal market grew at 22.4%
- Pain & Analgesics market grew at 21.1%
- Anti-infectives grew at 22.1%
- Anti-diabetic market grows at 29.8%
- Cardiac at 21.1% in Chronic Business
- Derma market grew by 23.2%
- Urology Market at 19.5%
- From regional perspective 14 regions have outgrown the IPM growth
- Haryana market grew the highest at 34.9% followed by South AP market at 33.0% & North AP Market at 32.3%
- No regions had negative growth in October 2015
- Amoxycillin + Clavulanic Acid Market grew at 17.8% whereas Glimepiride + Metformin grows at 20.9% at No 2.
- The markets of Paracetamol grew at 46.2%, Atorvastatin 15.5%, Probiotic Microbes at 27.6%, Cefixime 22.3%, Pantoprazole 20.6%, Montelukast + Levocetrizine at 23.7%, Glimepiride + Metformin + Pioglitazone at 24.3%, Vitamin-D at 29.5%, Hydroquinone + Mometasone + Tretinoin at -4.4%, Voglibose + Metformin + Glimepiride at 51.8%, Rosuvastatin at 28.1%, Protein Supplements at 17.7%, Azithromycin at 18.4%, Calcium Carbonate + Vit D3 market at 28.2%
- Mixtard leads the pack with 35 Crs followed Monocef at 33 Crs, Corex at 32 Crs for October 2015
- Brands who have gained ranks include Meronem (+167), Rotarix (+95), Trajenta (+46), Betnovate C (+45), Cardace (+41), Betnesol (+40), Betnovate N (+38), Rantac (+36), Mucaine (+32), Panderm Plus Rhoclone (+29), Omez (+28), Spasmoproxyvon Plus, Ascoril Plus(+23), Deriphyllin (+22), Januvia, Mifegest Kit (+20), Istamet (+18), Calpol (+17), Magnex (+15), Jalra , Dolo, Vertin(+14), Pantop (+13), Telma (+12), Janumet, Shelcal (+11), Sinarest (+4), in the top 100 Brands over October -14
- Brands that have moved up ranks fastest into Top 300 Brands for the month of October - 15 are Brilinta, Lonopin, Dexona, Mero, Meronem, Glizid M, Bevon among others
- Bifilac from Tablets India moves to the Top 300 Brand
- Total 223 Brands and 421 SKUs launched in October 2015
- Top New Brands for October -15 are Zitamet Plus, Ixarola, Jardiance
- Biggest New Launch by an MNC are Jardiance, Dulcosoft, Optive Fusion in October 2015
Comments
Post a Comment